Quanta Appoints Dr. Paul Komenda as New Chief Medical Officer
4 January 2019: Quanta Dialysis Technologies Ltd, a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company has appointed Dr. Paul Komenda as Chief Medical Officer. Dr. Komenda, Associate Professor of Medicine at the University of Manitoba, is a fellow of the American Society of Nephrology and has extensive clinical and academic experience.
Dr. Komenda previously served on the Scientific Advisory Board of NxStage Medical. He gained his medical qualification in 2001 from the University of Manitoba and is a board certified Nephrologist. Dr. Komenda studied health economics at the University of Calgary, holds a Masters in Health Administration and is also the Medical Director of the Home Dialysis Program and the Seven Oaks General Hospital in Manitoba.
Dr. Komenda has over 130 published peer reviewed articles in health services research and clinical nephrology and, with a specialist knowledge and interest in the field of home dialysis and health economics, Dr. Komenda is highly regarded as an expert in his field.
John E. Milad, Chief Executive Officer of Quanta, commented on the appointment: “We are excited to have Dr. Komenda join Quanta as our Chief Medical Officer. He brings a wealth of knowledge and expertise as a respected global thought-leader with extensive clinical experience in home dialysis. He will be invaluable to Quanta’s future success as we prepare to launch our innovative personal haemodialysis system, SC+, later this year in Europe.”
I have followed Quanta with interest over the past few years and have been inspired by the innovative work it is doing in the field of haemodialysis. SC+ is a unique system which offers patients flexibility, convenience, and control over their choice of treatment and I am excited to work with the team to bring this technology to market to improve the quality of life of dialysis patients.
Chief Medical Officer